Form 8-K - Current report:
SEC Accession No. 0001005286-24-000169
Filing Date
2024-11-26
Accepted
2024-11-26 17:29:29
Documents
18
Period of Report
2024-11-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lndc-20241126.htm   iXBRL 8-K 35763
2 EX-10.1 exhibit101-lifecorexlimite.htm EX-10.1 65712
3 EX-10.2 exhibit102-lifecorexlimite.htm EX-10.2 1917897
4 EX-99.1 pressrelease-lifecorebio.htm EX-99.1 7252
8 GRAPHIC pressrelease-lifecorebio001.jpg GRAPHIC 303866
9 GRAPHIC pressrelease-lifecorebio002.jpg GRAPHIC 37879
  Complete submission text file 0001005286-24-000169.txt   2946996

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lndc-20241126.xsd EX-101.SCH 1864
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lndc-20241126_lab.xml EX-101.LAB 21885
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lndc-20241126_pre.xml EX-101.PRE 12591
20 EXTRACTED XBRL INSTANCE DOCUMENT lndc-20241126_htm.xml XML 2690
Mailing Address 3515 LYMAN BOULEVARD CHASKA MN 55318
Business Address 3515 LYMAN BOULEVARD CHASKA MN 55318 9523684300
LIFECORE BIOMEDICAL, INC. \DE\ (Filer) CIK: 0001005286 (see all company filings)

EIN.: 943025618 | State of Incorp.: DE | Fiscal Year End: 0525
Type: 8-K | Act: 34 | File No.: 000-27446 | Film No.: 241505503
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)